$NEOV
NeoVolta Inc.

2023 Q4 Form 10-Q Financial Statement

#000168316823007984 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $1.018M $764.1K
YoY Change 79.48% -50.31%
Cost Of Revenue $812.0K $643.0K
YoY Change 71.6% -50.23%
Gross Profit $205.9K $121.2K
YoY Change 119.14% -50.72%
Gross Profit Margin 20.23% 15.86%
Selling, General & Admin $774.7K $560.0K
YoY Change -27.85% -39.09%
% of Gross Profit 376.3% 462.15%
Research & Development $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit 0.0% 0.0%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $774.7K $555.2K
YoY Change -28.37% -40.96%
Operating Profit -$568.8K -$434.0K
YoY Change -42.4% -37.51%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $12.78K $5.273K
YoY Change -227.55%
Pretax Income -$556.0K -$430.0K
YoY Change -43.69% -38.45%
Income Tax
% Of Pretax Income
Net Earnings -$556.0K -$428.7K
YoY Change -43.69% -38.63%
Net Earnings / Revenue -54.63% -56.1%
Basic Earnings Per Share -$0.02 -$0.01
Diluted Earnings Per Share -$0.02 -$0.01
COMMON SHARES
Basic Shares Outstanding 33.24M shares 33.16M shares
Diluted Shares Outstanding 33.23M shares 33.16M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.499M $1.820M
YoY Change -56.2% -54.42%
Cash & Equivalents $1.499M $1.824M
Short-Term Investments
Other Short-Term Assets $8.310K $50.00K
YoY Change -96.99% -53.5%
Inventory $1.982M $2.227M
Prepaid Expenses
Receivables $2.186M $2.076M
Other Receivables $0.00 $0.00
Total Short-Term Assets $5.675M $6.172M
YoY Change -21.71% -21.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.675M $6.172M
Total Long-Term Assets $0.00 $0.00
Total Assets $5.675M $6.172M
YoY Change -21.71% -21.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $11.77K $50.00K
YoY Change -33.73% -85.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.77K $49.38K
YoY Change -75.15% -85.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $11.77K $49.38K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $11.77K $50.00K
YoY Change -75.15% -85.41%
SHAREHOLDERS EQUITY
Retained Earnings -$19.42M -$18.87M
YoY Change 11.09% 14.37%
Common Stock $33.24K $33.16K
YoY Change 1.19% 1.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.663M $6.122M
YoY Change
Total Liabilities & Shareholders Equity $5.675M $6.172M
YoY Change -21.71% -21.0%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$556.0K -$428.7K
YoY Change -43.69% -38.63%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$323.5K -$179.1K
YoY Change -43.24% 51.59%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -323.5K -$179.1K
Cash From Investing Activities
Cash From Financing Activities 0.000 $0.00
Net Change In Cash -323.5K -$179.1K
YoY Change -43.24% -104.89%
FREE CASH FLOW
Cash From Operating Activities -$323.5K -$179.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001748137
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
001-41447
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
NeoVolta, Inc.
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5299263
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
13651 Danielson Street
CY2023Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Poway
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92064
CY2023Q3 dei City Area Code
CityAreaCode
(800)
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
364-5464
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33236091 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1823700 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2002789 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2075514 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1826385 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
2227222 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
2580571 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
45316 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
96119 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
6171752 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
6505864 usd
CY2023Q3 us-gaap Assets
Assets
6171752 usd
CY2023Q2 us-gaap Assets
Assets
6505864 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
49377 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39491 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
49377 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
39491 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33155127 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33155127 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33155127 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33155127 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
33155 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
33155 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24957163 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24872446 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18867943 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18439228 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6122375 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6466373 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6171752 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6505864 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
764130 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1537836 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
642958 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1291960 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
121172 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
245876 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
555160 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
919428 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20900 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
555160 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
940328 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-433988 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-694452 usd
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
5273 usd
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
-0 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
4134 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5273 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4134 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-428715 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-698586 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33155127 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33155127 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29009882 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29009882 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6466373 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
84717 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-428715 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6122375 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2617224 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3780405 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1179286 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
591816 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-698586 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
7470145 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-428715 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-698586 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
84717 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
591816 usd
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
110000 usd
CY2022Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
359129 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
758218 usd
CY2023Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-353349 usd
CY2022Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-601557 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-50803 usd
CY2022Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-131469 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-205600 usd
CY2023Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
9886 usd
CY2022Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
219423 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-179089 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-118139 usd
CY2023Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
CY2022Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
3780405 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3780405 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-179089 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3662266 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2002789 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330385 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1823700 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3992651 usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q3 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q3 NEOV Conversion Of Convertible Debt And Accrued Interest Into Common Stock
ConversionOfConvertibleDebtAndAccruedInterestIntoCommonStock
0 usd
CY2022Q3 NEOV Conversion Of Convertible Debt And Accrued Interest Into Common Stock
ConversionOfConvertibleDebtAndAccruedInterestIntoCommonStock
1179286 usd
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1323700 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
1400000 usd
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1732807 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2353055 usd
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
494415 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
227516 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
2227222 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
2580571 usd
CY2023Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_zsfgG7K0ISed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span id="xdx_864_zR8BzcUgUpDa">Use of Estimates</span></i> – Management has made a number of estimates and assumptions in preparing these financial statements in conformity with accounting principles generally accepted in the United States of America. Actual results could differ from those estimates. As a result of the continued spread of the COVID-19 coronavirus since early 2020, economic uncertainties have arisen which could impact business operations, supply chains, energy demand, and commodity prices that are beyond our control. Overall, we have not experienced a material adverse impact to our economic performance or ability to continue our business operations as a result of COVID-19. We continue to monitor COVID-19, but do not believe it will have a material unfavorable impact to our future financial performance at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
600000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
490000 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0 usd
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1823700 usd
CY2023Q3 NEOV Working Capital
WorkingCapital
6122375 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1179750 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1179750 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.02
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1179750 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.02
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y9M18D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1179750 shares
CY2023Q3 NEOV Warrants Exercisable Weighted Average Exercise Price
WarrantsExercisableWeightedAverageExercisePrice
4.02
CY2023Q3 NEOV Warrants And Rights Outstanding Term Exercisable
WarrantsAndRightsOutstandingTermExercisable
P3Y9M18D
CY2023Q3 NEOV Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable
0 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
84717 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
591816 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
neov-20230930_lab.xml Edgar Link unprocessable
neov-20230930_pre.xml Edgar Link unprocessable
0001683168-23-007984-index-headers.html Edgar Link pending
0001683168-23-007984-index.html Edgar Link pending
0001683168-23-007984.txt Edgar Link pending
0001683168-23-007984-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
neov-20230930.xsd Edgar Link pending
neovolta_ex3101.htm Edgar Link pending
neovolta_ex3102.htm Edgar Link pending
neovolta_ex3201.htm Edgar Link pending
neovolta_ex3202.htm Edgar Link pending
neovolta_i10q-093023.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
neov-20230930_cal.xml Edgar Link unprocessable
neov-20230930_def.xml Edgar Link unprocessable
neovolta_i10q-093023_htm.xml Edgar Link completed